ClinicalTrials.gg
Status unknownNCT05506462Updated Aug 22, 2022

An EEG Study of Intravenous Ketamine for Major Depression Disorder

A Phase 4 interventional study of Ketamine Hydrochloride in Major Depressive Disorder, sponsored by Ehave Inc.. Status unknown. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-08-22.

Sponsored by Ehave Inc. · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies testing ketamine in Depressive Disorder, Major — 21 open to participants now, 26 under way, 5 of them phase 3. Ketamine · Depressive Disorder, Major.

Planned enrollment
48th of 89
35 · median 38
Started
2023
the only one that year
Phase 4
16 of 89
2 open now
Registered
71st of 89
by date

Among the 89 studies testing ketamine in Depressive Disorder, Major, this one is the 48th largest by planned enrollment, is the only one that started in 2023, is one of 16 in phase 4, and was the 71st registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

21 of the 89 studies testing ketamine in Depressive Disorder, Major are open now, in 9 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing ketamine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

There are many common pharmacological treatments for major depression disorder (MDD), however the efficacy of these drugs often fails in severe cases. Intravenous (IV) administered ketamine may offer the potential for remission of the symptoms in patients with MDD; however it has not yet been approved by FDA for this purpose. This study will make use of an electroencephalography (EEG) machine to measure the brain's activity and response while the IV ketamine is being delivered. The objective of this study is to characterize the change in EEG response of patients with MDD, during and 4 weeks after a course of IV ketamine infusions.

Read the detailed description

This study will enroll 35 patients with major depressive disorder. Candidates for participation in the study will typically be either referred to the clinic through their healthcare provider or will have sought out participation on their own accord based on advertising. Subjects will be screened for eligibility and suitable patients will be invited to attend a screening visit in the clinic and complete informed consent.

Upon determining eligibility, subjects will have their first treatment session booked within 42 days of screening (Baseline, visit 0). Three subsequent weekly (±3 days) ketamine therapy treatment sessions will occur on days 7, 14 and 21, for a total of four ketamine infusions over four weeks. All patients will return for a follow-up visit at 4-weeks post final treatment visit, day 49.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Intravenous ketamine
  • Electroencephalogram (EEG) monitoring
  • Major depressive disorder
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals between 18 and 70 years of age, inclusive
  2. Adult patients with a documented primary Axis I clinical diagnosis meeting criteria from the for a major depressive disorder
  3. Score of \<15 on the DES
  4. Moderate to severe symptoms objectively documented using MADRS total score of ≥ 20
  5. Ability to maintain scheduled appointments for screenings, 4 treatment visits and follow-up EEG visit.
  6. History of major depressive disorder.
  7. Females of who are sexually active must agree to use two forms of . A pregnancy test will be performed before the first treatment.
  8. Must have stable residence address, internet and mobile phone.
  9. Must speak fluent English.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to ketamine or any other drug used in the study.
  2. Use of ketamine in a therapeutic model within the preceding 12 months of the study.
  3. Current or any history of schizoaffective disorder(s).
  4. Score of ≥ 15 on DES
  5. History of illicit active substance abuse or dependence including ketamine as determined on by the SCID-5-CT and/or drug urine screening during study visits.
  6. Pregnancy, breastfeeding or desire to become pregnant during the course of the study.
  7. Serious, unstable illnesses including, but not limited to; hepatic, gastro-intestinal, respiratory, cardiovascular (including ischemic heart disease and coronary heart disease). History of ischemic stroke, atrial fibrillation, severe endocrinological, neurological, immunological or hematological disease.
  8. Any history of cerebral vascular events including stroke, bleeding into the brain and subdural hematomas.
  9. Any implantable metallic device(s) or implant(s) above the level of shoulders.
  10. Any non-removable metallic piercings.
  11. Patients with cochlear implants and non-removable hearing aids.
  12. Current use of: Dilantin, Depakote, Phenobarbital, Gabapentin, Pregabalin and Benzodiazepines. Certain candidates with long use of Benzodiazepines may qualify at PI's discretion.
  13. Severe labile hypertension.
  14. Significant uncontrolled hypertension (i.e., SBP > 150 mmHG, DBP > 100 mmHG)
  15. Uncontrolled diabetes mellitus.
  16. Patients on renal dialysis.
  17. Inability to achieve consistent IV access.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Ketamine

    50-60 minutes intravenous infusion of 60mg ketamine

    Drug: Ketamine Hydrochloride

Interventions

  • Patients with a diagnosis of Major Depressive Disorder (MDD) will be enrolled to receive four 50-60 minute infusions of 60mg ketamine hydrochloride

    Also known as: NDC 67457-108-00

06

What researchers measure

Primary outcomes

  1. Characterizing the changes in EEG reading frequencies from pre- IV ketamine infusion treatment (baseline).

    Alpha, Beta, Delta, Theta and Gamma frequencies will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution

    Time frame: 30-minute pre-treatment baseline and throughout infusion (approximately 50-60 minutes)

  2. Characterizing the changes in EEG reading waveforms from pre- IV ketamine infusion treatment (baseline).

    Alpha, Beta, Delta, Theta and Gamma waveforms will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution

    Time frame: 30-minute pre-treatment baseline and throughout infusion (approximately 50-60 minutes)

  3. Characterizing the changes in EEG reading amplitudes from pre- IV ketamine infusion treatment (baseline).

    Alpha, Beta, Delta, Theta and Gamma amplitude will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution

    Time frame: 30-minute pre-treatment baseline and throughout infusion (approximately 50-60 minutes)

  4. Characterizing the changes in EEG reading patterns from pre- IV ketamine infusion treatment (baseline).

    Alpha, Beta, Delta, Theta and Gamma reading patterns will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution

    Time frame: 30-minute pre-treatment baseline and throughout infusion (approximately 50-60 minutes)

  5. Characterizing the changes in EEG reading frequencies from pre- IV ketamine infusion treatment (baseline) and 4 weeks post-treatment course

    Alpha, Beta, Delta, Theta and Gamma frequencies will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution

    Time frame: Pre-treatment baseline, 4 weeks post-treatment course

  6. Characterizing the changes in EEG reading waveforms from pre- IV ketamine infusion treatment (baseline) and 4 weeks post-treatment course

    Alpha, Beta, Delta, Theta and Gamma waveforms will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution

    Time frame: Pre-treatment baseline, 4 weeks post-treatment course

  7. Characterizing the changes in EEG reading amplitudes from pre- IV ketamine infusion treatment (baseline) and 4 weeks post-treatment course

    Alpha, Beta, Delta, Theta and Gamma amplitude will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution

    Time frame: Pre-treatment baseline, 4 weeks post-treatment course

  8. Characterizing the changes in EEG reading patterns from pre- IV ketamine infusion treatment (baseline) and 4 weeks post-treatment course

    Alpha, Beta, Delta, Theta and Gamma amplitude will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution

    Time frame: Pre-treatment baseline, 4 weeks post-treatment course

Secondary outcomes

  1. Incidence of medically significant changes in blood pressure during ketamine infusion

    Time frame: Pre-treatment baseline; treatment initiation, 0 minutes; 20 minutes, 40 minutes; 60 minutes post-infusion

  2. Incidence of medically significant changes in Oxygen Saturation (SpO2) during ketamine infusion

    Time frame: Pre-treatment baseline; treatment initiation, 0 minutes; 20 minutes, 40 minutes; 60 minutes post-infusion

  3. Incidence of medically significant changes in heart rate during ketamine infusion

    Time frame: Pre-treatment baseline; treatment initiation, 0 minutes; 20 minutes, 40 minutes; 60 minutes post-infusion

  4. Incidence of medically significant changes in respiratory rate during ketamine infusion

    Time frame: Pre-treatment baseline; treatment initiation, 0 minutes; 20 minutes, 40 minutes; 60 minutes post-infusion

  5. Changes from baseline in the Dissociative Experiences Scale (DES) Total Score

    The Dissociative Experiences Scale (DES) is a 28-item scale assessing the subject's experiences in his/her daily life. The subject determines to what degree he/she has been facing the situation by selecting a percentage from 0% (never) to 100% (always), with 10% increments in between. Higher scores mean higher severity

    Time frame: Baseline (Day 0), follow-up visit (Day 42)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2023; primary completion for Jan 2024, 12 months later.

Of 98 phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2022
First posted
Aug 18, 2022
StartEst.
Jan 2023
Primary completionEst.
Jan 2024
CompletionEst.
Feb 2024
Last update
Aug 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05506462
Lead sponsor
Ehave Inc.
Collaborators
Tristar Wellness
Responsible party
Sponsor
First posted
Aug 18, 2022
Start date
Jan 2023 (estimated)
Primary completion
Jan 2024 (estimated)
Completion
Feb 2024 (estimated)
Last update
Aug 22, 2022

Study contacts

Jeffrey D Kamlet, MD
Contact
jeffrey@tristarwell.com
305 604 9595
Jeffrey D Kamlet, MD
principal investigator · Tristar Wellness

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion